Why the study?
Despite available treatments markedly improving prognosis, pulmonary arterial hypertension remains an incurable, life-limiting condition leading to right ventricular failure.
This review highlights the shift in PAH management towards early aggressive combination therapy and the development of novel drugs targeting pulmonary vascular remodeling to prevent right ventricular failure.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lareo et al. (2021) conducted a review in Pulmonary arterial hypertension. Pharmacotherapy for pulmonary arterial hypertension was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: